DOI: 10.4244/EIJV8I9A170

First-in-human experience: percutaneous renal denervation through a false lumen fenestration in aortic dissection type B

Sebastian Ewen*, MD; Felix Mahfoud, MD; Michael Böhm, MD

A 61-year-old man (height 181 cm, weight 110 kg) presented to our clinic with dyspnoea (NYHA Class II) and progressive chest and abdominal pain. Medical history included an aortic dissection type B with perfusion of the left kidney from the false lumen, diagnosed in 2009 (Figure 1A and Figure 1B). The patient was receiving five antihypertensive drugs (bisoprolol 5 mg ½-0-½, hydrochlorothiazide 25 mg 1-0-0, amlodipine 10 mg 1-0-0, urapidil 90 mg 1-0-1, moxonidine 0.3 mg 1-0-1). Office blood pressure (BP) was 160/95 mmHg. Ambulatory 24-hour BP monitoring confirmed true treatment resistance (mean 141/91 mmHg, non-dipping pattern).

Figure 1. A) Magnetic resonance angiography (MRA) of the aortic arch, showing the entry of the dissection distal of the left subclavian artery. B) MRA, showing the descending aorta with the dissection membrane. Angiography of C) the right renal artery, and D) the left renal artery, before renal denervation (after fenestration).

Renal denervation was performed via femoral access. An 8 Fr IMA guiding catheter (Cordis, Johnson & Johnson, Warren, NJ, USA) was placed into the true aortic lumen at the level of the left renal artery. After a fenestration manoeuvre of the intima flap, performed using an IRON MAN PTCA wire (Abbott Vascular, Redwood City, CA, USA), the Symplicity™ radiofrequency catheter (Medtronic Inc., Minneapolis, MN, USA) was introduced and advanced to the distal segment of the renal artery under fluoroscopy (Figure 1C and Figure 1D, Moving image 1 and Moving image 2). Five treatments of the left artery and six of the right artery were successfully applied.

At three and six-month follow-up, ambulatory 24-hour BP was reduced by 13/10 mmHg and 14/9 mmHg (mean daytime 130/83 mmHg; mean night-time 122/79 mmHg), respectively (Online Figure 1). Six months after treatment, BP was controlled to target (office 130/90 mmHg). MRA showed no sign of complications at six-month follow-up.

Conflict of interest statement

The institution has received scientific support from Medtronic/Ardian. M. Böhm and F. Mahfoud have received speaker honoraria and consultancy fees from Medtronic/Ardian and are supported by Deutsche Forschungsgemeinschaft (KFO 196). F. Mahfoud is supported by Deutsche Hochdruckliga. S. Ewen has no conflicts of interest to declare.

Online data supplement

Online Figure 1. Blood pressure reduction after renal denervation in a patient with aortic dissection type B after three and six months (ambulatory 24-hour blood pressure monitoring).

Moving image 1. Angiography of the right renal artery, before renal denervation (after fenestration).

Moving image 2. Angiography of the left renal artery, before renal denervation (after fenestration).

Online Figure 1. Blood pressure reduction after renal denervation in a patient with aortic dissection type B after three and six months (ambulatory 24-hour blood pressure monitoring).

Supplementary data

To read the full content of this article, please download the PDF.

Moving image 1.
Moving image 2.
Volume 8 Number 9
Jan 18, 2013
Volume 8 Number 9
View full issue


Key metrics

On the same subject

Editorial

10.4244/EIJ-E-24-00010 Apr 15, 2024
Timing of revascularisation in acute coronary syndromes with multivessel disease – two sides of the same coin
Stähli B and Stehli J
free

Editorial

10.4244/EIJ-E-24-00006 Apr 15, 2024
The miracle of left ventricular recovery after transcatheter aortic valve implantation
Dauerman H and Lahoud R
free

Research Correspondence

10.4244/EIJ-D-23-01046 Apr 15, 2024
Feasibility and safety of transcaval venoarterial extracorporeal membrane oxygenation in severe cardiogenic shock
Giustino G et al

State-of-the-Art

10.4244/EIJ-D-23-00836 Apr 15, 2024
Renal denervation in the management of hypertension
Lauder L et al
free

Original Research

10.4244/EIJ-D-23-00643 Apr 15, 2024
A study of ChatGPT in facilitating Heart Team decisions on severe aortic stenosis
Salihu A et al
Trending articles
337.88

State-of-the-Art Review

10.4244/EIJ-D-21-00904 Apr 1, 2022
Antiplatelet therapy after percutaneous coronary intervention
Angiolillo D et al
free
283.98

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
226.03

State-of-the-Art Review

10.4244/EIJ-D-21-00426 Dec 3, 2021
Myocardial infarction with non-obstructive coronary artery disease
Lindahl B et al
free
209.5

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
168.4

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
150.28

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
103.48

Expert consensus

10.4244/EIJ-E-22-00018 Dec 4, 2023
Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations
Lunardi M et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved